



## Corrigendum to “Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma “in vitro” [Biomed. Pharmacother. 66 (2012) 64–69]

Erica Mie Akagi<sup>a</sup>, Paulo Luiz de Sá Júnior<sup>a</sup>, Simone Michaela Simons<sup>a</sup>, Maria Helena Bellini<sup>b</sup>, Sandra Alves Barreto<sup>a</sup>, Ana Marisa Chudzinski-Tavassi<sup>a,\*</sup>

<sup>a</sup> Laboratory of Molecular Biology, Butantan Institute, Avenue Vital Brazil, 1500, CEP 05503-900, São Paulo, SP, Brazil

<sup>b</sup> Institute of Energy and Nuclear Research, IPEN, São Paulo, Brazil

It has come to our attention that in the work referenced above Figure 1 a wrong photograph was published. As a result of this finding, we are correcting our article to change the Figure 1A corresponding to controls of 24 and 48h without treatment with the molecule studies named Amblyomin-X.




Fig. 1. Overview and MTT of Renca cells treated with Amblyomin-X. Cytological aspects of Renca cells treated with Amblyomin-X (0.6 or 1.0 mM) for 24 or 48 hours treatment. A. Changes on cell architecture were observed in both 24 and 48 hours treatment such as cell contraction, loss of inter-cell elongations and dispersed cell. After 48 hours there were formations of many cell aggregates. B and C. Viability assessed by the formation of formazan crystals in adhered cells. Mean  $\pm$  SD determined from three independent experiments. \*\*\*P < 0.05 compared to control group, as determined by “one-way” ANOVA.

DOI of original article: <https://doi.org/10.1016/j.bioph.2011.11.015>

\* Corresponding author.

E-mail address: [ana.chudzinski@butantan.gov.br](mailto:ana.chudzinski@butantan.gov.br) (A.M. Chudzinski-Tavassi).

<https://doi.org/10.1016/j.bioph.2019.109108>